Page 1

impedimedⓇ 28 April 2021 ASX ANNOUNCEMENT APPENDIX 4C - Quarter Ended 31 March 2021 ( Q3 FY'21 ) Brisbane , Australia - ImpediMed Limited ( ASX.IPD ) , a medical technology company that uses bioimpedance spectroscopy ( BIS ) technology to generate powerful data to maximise patient health , today released its Appendix 4C - Quarterly Cash Flow report for the period ended 31 March 2021 . Revenue Summary : • Record quarter for Total Revenue for Q3 FY'21 of $ 2.3 million , + 35 % the previous corresponding period ( pcp ) ( Q3 FY'20 : $ 1.7 million ) and + 10 % quarter over quarter . Record quarter for SOZOⓇ Revenue for Q3 FY'21 of $ 2.1 million , + 50 % pcp ( Q3 FY'20 : $ 1.4 million ) and + 11 % quarter over quarter . Record quarter for SOZO SaaS Revenue for Q3 FY'21 of $ 1.8 million , + 100 % pcp and + 38 % quarter over quarter . For personal use only ○ SOZO SaaS Revenue of $ 1.1 million from Core Business ' . о SOZO SaaS Revenue of $ 0.7 million from Clinical Business " . Cash Flow Summary : • Cash on hand as at 31 March 2021 of $ 23.9 million . • Cash receipts from customers for the quarter of $ 2.1 million . Receipt of an additional $ 8.8 million from the exercise of options issued to subscribers in the Entitlement Offer . ○ In total , the Group received $ 17.9 million of the $ 18.2 million ( 98 % ) from the exercise of Options issued to subscribers in the Entitlement Offer . Net operating cash outflows of $ 3.2 million , significantly better than the forecasted $ 4.0 million net operating cash outflow announced to the market on 28 January 2021 . Effective 1 January 2021 , the temporary reductions to the Non - executive Director fees were removed . The Company expects net operating cash outflows to remain below $ 4.0 million for Q4 FY'21 , which includes some additional spend on product development for heart and renal failure . Related Parties : During the quarter , the Company issued shares to Directors as equity- based remuneration in lieu of cash , as described in Item 6 of the Appendix 4C . Operational Summary and Key SaaS Metrics : • • • Record quarter for Patient Tests , with over 32,000 recorded in Q3 FY'21 , + 59 % pcp and + 16 % quarter over quarter . Annual Recurring Revenue of $ 8.2 million , + 49 % pcp and + 5 % quarter over quarter . ARR of $ 5.4 million from Core Business . ○ ARR of $ 2.8 million from Clinical Business . iv Contracted Revenue Pipeline ✓ of $ 14.5 million , + 20 % pcp and -2 % quarter over quarter . Churn Rate remains low at just 1 % . Renewal Rate of 100 % on contracts up for renewal during the quarter . 43 new SOZO devices sold , totaling more than 720 SOZO units sold since launch . о Strong progress despite headwinds from COVID - 19 and Texas storms . о This does not include any units supplied for the AstraZeneca trials .